Emerging Treatment Options for BRAF-mutant Colorectal Cancer ~ virtual live webinar with CNE

Wednesday, August 18, 2021 • 7:00 PM – 8:30 PM EDT

Rebroadcast: Thursday, August 26, 2021 • 7:00 PM – 8:30 PM EDT

Treatment Options for CRC Patients With BRAF Mutation

The BRAF V600E mutation occurs in approximately 10% of patients with metastatic colorectal cancer (CRC), with recent estimates ranging from as low as 5% to as high as 21%. This mutation identifies a distinct subtype of CRC that has a poor prognosis. Initial standard chemotherapy for BRAF V600E–mutated CRC results in poor outcomes, and intensifying therapy attempts have met with limited success. After failure of initial therapy, subsequent treatment lines have minimal effect, and rapidly progressive disease and short overall survival are seen. This webinar will describe most suitable treatment options for CRC patients with BRAF mutation and discuss new emerging agents.

Earn 1.50 / AMA PRA Category 1 Credit(s)™, or 1.50 / ANCC Contact Hours.